Skip to content
Pharmacy Tirzepatide

A plain-numbers reading desk for the tirzepatide trial record — what SURPASS-2 and SURMOUNT-5 measured head-to-head against semaglutide.

About Pharmacy Tirzepatide and the Studies It Uses

What Pharmacy Tirzepatide can tell you

Used by prescription, tirzepatide is a shot studied for blood sugar, weight, and other health problems. Pharmacy Tirzepatide explains what those studies found in plain words. It doesn't treat you, give a diagnosis, write a prescription, or sell anything.

The site name tells you the subject, not a service. This isn't a pharmacy or clinic. No product changes hands here.

We check each number against the paper that reported it. The Tirzepatide references page gives a direct link to each paper and its medical-library listing. A numbered claim leads back to that list. You can read the paper for yourself.

Which Tirzepatide findings are covered here

Tirzepatide copies both gut hormones in 1 drug. The FDA approved it for type 2 diabetes in May 2022. Long-term care for weight came in November 2023. Much of this guide compares tirzepatide with semaglutide.

The main papers are:

  • In 2021, a large phase 3 study, meaning a large late test, covered type 2 diabetes. The direct study SURPASS-2 was the 1,879-patient comparison with semaglutide 1 mg
  • Other phase 3 studies covered obesity or overweight. SURMOUNT-1 followed 2,539 people for 72 weeks. SURMOUNT-5 was the direct 751-patient comparison. SURMOUNT-4 checked what happened when the drug continued or stopped
  • Early work appeared in 2018 and 2020
  • A nine-trial safety review appeared in 2023
  • Work from 2024–2026 included a review of medical records, a two-year second look called SURPASS-4 and a daily-life report from the weight study SURMOUNT-5

We don't give personal dose advice, prescribe care, explain insurance, or tell you where to get the drug.

How each Tirzepatide claim is explained

Four rules guide this site.

  1. The finding comes first. You get the main result before the background.
  2. Each number has a paper. The number beside a claim points to the paper that reported it.
  3. The drug keeps one name. Tirzepatide is the standard name, so brand names aren't needed.
  4. Unknowns stay clear. We say when work is early, paid for by the drug maker, limited to cells or animals, or unproved in people.